Mechanism of Growth Hormone Effects on Adipose Tissue
| Status: | Completed |
|---|---|
| Conditions: | Obesity Weight Loss |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 40 - 70 |
| Updated: | 4/21/2016 |
| Start Date: | April 1999 |
| End Date: | December 2000 |
Growth hormone treatment in humans has been shown to decrease body fat. This study aims to
determine what adipose tissue depots are affected by GH and what is the mechanism.
determine what adipose tissue depots are affected by GH and what is the mechanism.
Growth hormone (GH) replacement in GH deficient adults results in an improvement in
metabolic status, an increase in lean body mass and a reduction in visceral adiposity. GH
might also decrease visceral adiposity in obese adults that are not GH deficient.
The objective of the study is to determine the effects of GH on the metabolic syndrome and
visceral adiposity in men with low blood levels of IGF-1 and the durability of these effects
after stopping GH therapy. We will use a double blind, placebo controlled 6 month
intervention trial followed by a blinded follow-up period of 6 months. Thirty non-diabetic
middle aged men with central adiposity (BMI > 27 kg/m2, waist circumference > 102 cm) will
participate.
metabolic status, an increase in lean body mass and a reduction in visceral adiposity. GH
might also decrease visceral adiposity in obese adults that are not GH deficient.
The objective of the study is to determine the effects of GH on the metabolic syndrome and
visceral adiposity in men with low blood levels of IGF-1 and the durability of these effects
after stopping GH therapy. We will use a double blind, placebo controlled 6 month
intervention trial followed by a blinded follow-up period of 6 months. Thirty non-diabetic
middle aged men with central adiposity (BMI > 27 kg/m2, waist circumference > 102 cm) will
participate.
Inclusion Criteria:
- Male, aged 40-70
- Central obesity defined as waist circumference greater than 102 cm and BMI > 27 and <
35 kg/m2
- No weight loss in last 12 months
- Total IGF-1 level < 241 ng/ml (~25th percentile for the assay)
- Body habitus which permitted accurate CT scan acquisition and analysis.
Exclusion Criteria:
- Significant neurologic, metabolic, endocrine, cardiac, respiratory or
gastrointestinal disease
- Diabetes
- Known coronary heart disease
- Exercised more than 3 hours per week
- Unwilling or unable to abstain from alcohol for 72 hours prior to the measurements of
energy expenditure and fasting blood work
We found this trial at
1
site
Pennington Biomedical Research Center Unlike other medical research facilities where science occurs in separate labs...
Click here to add this to my saved trials
